Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

Akebia Therapeutics Company

AKBA
US00972D1054
A1XF0S

Price

1.63
Today +/-
+0.04
Today %
+2.48 %
P

Akebia Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Akebia Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Akebia Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Akebia Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Akebia Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Akebia Therapeutics Stock Price History

DateAkebia Therapeutics Price
10/28/20241.63 undefined
10/25/20241.59 undefined
10/24/20241.58 undefined
10/23/20241.59 undefined
10/22/20241.64 undefined
10/21/20241.37 undefined
10/18/20241.34 undefined
10/17/20241.33 undefined
10/16/20241.33 undefined
10/15/20241.31 undefined
10/14/20241.32 undefined
10/11/20241.32 undefined
10/10/20241.28 undefined
10/9/20241.28 undefined
10/8/20241.32 undefined
10/7/20241.32 undefined
10/4/20241.33 undefined
10/3/20241.32 undefined
10/2/20241.34 undefined
10/1/20241.28 undefined

Akebia Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Akebia Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Akebia Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Akebia Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Akebia Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Akebia Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Akebia Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Akebia Therapeutics’s growth potential.

Akebia Therapeutics Revenue, EBIT and net profit per share

DateAkebia Therapeutics RevenueAkebia Therapeutics EBITAkebia Therapeutics Net Income
2029e830.17 M undefined0 undefined514.79 M undefined
2028e452.89 M undefined248.47 M undefined233.8 M undefined
2027e334 M undefined119.2 M undefined110.47 M undefined
2026e251.37 M undefined37.69 M undefined31.1 M undefined
2025e181.1 M undefined-63.09 M undefined-55.05 M undefined
2024e175.44 M undefined-48.17 M undefined-52.19 M undefined
2023194.62 M undefined-44.48 M undefined-51.93 M undefined
2022292.5 M undefined-34.7 M undefined-94.2 M undefined
2021211.7 M undefined-249.5 M undefined-282 M undefined
2020294.6 M undefined-242.8 M undefined-384.8 M undefined
2019335 M undefined-286.3 M undefined-279.7 M undefined
2018207.7 M undefined-178.2 M undefined-143.6 M undefined
2017181.2 M undefined-76.7 M undefined-73.7 M undefined
20161.5 M undefined-136.5 M undefined-135.7 M undefined
20150 undefined-61.5 M undefined-60.7 M undefined
20140 undefined-37.9 M undefined-123.9 M undefined
20130 undefined-15.9 M undefined-69.1 M undefined
20120 undefined-8.5 M undefined-11.5 M undefined
20110 undefined-15.5 M undefined-18.3 M undefined

Akebia Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000001181207335294211292194175181251334452830
------18,000.0014.3661.84-12.24-28.2338.39-33.56-9.793.4338.6733.0735.3383.63
------100.0097.1066.2755.1051.1892.4779.38------
000000181201222162108270154000000
-15-8-15-37-61-136-76-178-286-242-249-34-44-48-63371192480
------13,600.00-41.99-85.99-85.37-82.31-118.01-11.64-22.68-27.43-34.8114.7435.6354.87-
-18-11-69-123-60-135-73-143-279-384-282-94-51-52-5531110233514
--38.89527.2778.26-51.22125.00-45.9395.8995.1037.63-26.56-66.67-45.741.965.77-156.36254.84111.82120.60
18.318.318.315.426.537.743.558118.4138.5165.9182.8187.47000000
-------------------
Details

Keystats

ⓘ

Revenue and Growth

The Akebia Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Akebia Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
6.41.632.6108.9138.5260.3317.8321.6147.7268.7149.890.542.93
0.10.10.10033.834.216.738.926.951.640.339.29
0000000000000
0000000114.2116.36136.621.615.69
0.80.50.71.52.62.26.315.76.614.933.132.920.24
7.32.233.4110.4141.1296.3358.3468.2309.5371.5271.1185.3118.15
0000.20.52.63.6839.435.540.634.416.05
0000000000000
0000000000000
0000000328.2291.2144.2108.172.136.04
000000055.155.155.1595959.04
001.20.31.41.32.3137763850.45.412.42
001.20.51.93.95.9528.3461.7272.8258.1170.9123.55
7.32.234.6110.9143300.2364.2996.5771.2644.3529.2356.2241.7
                         
53.656.9157.80000000000
0000.210.290.370.491.151.191.431.541.561.58
-48.2-59.6-127.1-100.7-161.4-297.1-370.8-514.4-794.1-1,177.5-1,462.8-1,557-1,608.95
000-100-2000-400-30000006
0000000000000
5.4-2.730.7104.2131.268.2122.6635.9394.7247.6745.2-30.58
1.40.40.722.32742.839.241.333.61814.64
0.40.43.24.99.630.351.5150.9129.1130.610975.867.74
04.20008282.75739.815.220.93.70
00000001500000
000000000097.53217.5
1.853.96.911.9114.3141.2265.7208.1187.1261129.599.87
0000000075.896.4034.117.18
00000006.600000
00000.1117.8100.688.392.5113194.3187.2155.23
00000.1117.8100.694.9168.3209.4194.3221.3172.42
1.853.96.912232.1241.8360.6376.4396.5455.3350.8272.29
7.22.334.6111.1143.2300.3364.4996.5771.1644.1529.3356241.7
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Akebia Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Akebia Therapeutics's financial health and stability.

Assets

Akebia Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Akebia Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Akebia Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Akebia Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2011201220132014201520162017201820192020202120222023
-15-8-13-37-60-135-76-143-279-383-282-92-51
000000023833373737
0000000000000
0013218677-105-13-108-10-20
0111291221551012771231020
0000000000966
0000000000000
-14-7-11-27-5257-56-97-257-110-252-73-23
00000-2-1-1-60000
01-11-65-1312-17736211-403900
01-11-65-1315-17538217-394000
0000000000000
0000000062190-33-32
18243104826611696262118876
172421048366116968823113314-25
00-1000000044400
0000000000000
2-3191116137-117354281-79-58-48
-14.18-7.21-11.35-27.71-52.8255.25-57.78-99.1-264.1-110.71-253.03-73.26-23.38
0000000000000

Akebia Therapeutics stock margins

The Akebia Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Akebia Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Akebia Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Akebia Therapeutics's sales revenue. A higher gross margin percentage indicates that the Akebia Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Akebia Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Akebia Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Akebia Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Akebia Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Akebia Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Akebia Therapeutics Margin History

Akebia Therapeutics Gross marginAkebia Therapeutics Profit marginAkebia Therapeutics EBIT marginAkebia Therapeutics Profit margin
2029e79.58 %0 %62.01 %
2028e79.58 %54.86 %51.62 %
2027e79.58 %35.69 %33.07 %
2026e79.58 %14.99 %12.37 %
2025e79.58 %-34.84 %-30.4 %
2024e79.58 %-27.46 %-29.75 %
202379.58 %-22.85 %-26.68 %
202292.31 %-11.86 %-32.21 %
202151.25 %-117.86 %-133.21 %
202055.13 %-82.42 %-130.62 %
201966.42 %-85.46 %-83.49 %
201896.97 %-85.8 %-69.14 %
2017100 %-42.33 %-40.67 %
201679.58 %-9,100 %-9,046.67 %
201579.58 %0 %0 %
201479.58 %0 %0 %
201379.58 %0 %0 %
201279.58 %0 %0 %
201179.58 %0 %0 %

Akebia Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Akebia Therapeutics earnings per share therefore indicates how much revenue Akebia Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akebia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akebia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akebia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akebia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Akebia Therapeutics Revenue, EBIT and net profit per share

DateAkebia Therapeutics Sales per ShareAkebia Therapeutics EBIT per shareAkebia Therapeutics Earnings per Share
2029e3.95 undefined0 undefined2.45 undefined
2028e2.15 undefined0 undefined1.11 undefined
2027e1.59 undefined0 undefined0.53 undefined
2026e1.2 undefined0 undefined0.15 undefined
2025e0.86 undefined0 undefined-0.26 undefined
2024e0.83 undefined0 undefined-0.25 undefined
20231.04 undefined-0.24 undefined-0.28 undefined
20221.6 undefined-0.19 undefined-0.52 undefined
20211.28 undefined-1.5 undefined-1.7 undefined
20202.13 undefined-1.75 undefined-2.78 undefined
20192.83 undefined-2.42 undefined-2.36 undefined
20183.58 undefined-3.07 undefined-2.48 undefined
20174.17 undefined-1.76 undefined-1.69 undefined
20160.04 undefined-3.62 undefined-3.6 undefined
20150 undefined-2.32 undefined-2.29 undefined
20140 undefined-2.46 undefined-8.05 undefined
20130 undefined-0.87 undefined-3.78 undefined
20120 undefined-0.46 undefined-0.63 undefined
20110 undefined-0.85 undefined-1 undefined

Akebia Therapeutics business model

Akebia Therapeutics Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, USA. The company was founded in 2007 and focuses on the development and marketing of medications for the treatment of kidney diseases and other diseases. Akebia Therapeutics is one of the most popular companies on Eulerpool.com.

Akebia Therapeutics Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Akebia Therapeutics Revenue by Segment

Segmente202320222021202020192018
Product revenue, net170.3 M USD177.1 M USD142.2 M USD128.9 M USD--
License, collaboration and other revenue24.32 M USD115.54 M USD71.36 M USD166.41 M USD1.07 M USD87.32 M USD
Product Revenue, Net----111.12 M USD6.82 M USD

Akebia Therapeutics SWOT Analysis

Strengths

Akebia Therapeutics Inc has several strengths that contribute to its competitive advantage in the market. Firstly, the company demonstrates strong expertise in the development of innovative therapeutics, particularly in the field of kidney diseases. This expertise allows Akebia to create effective and novel treatment options for patients, setting them apart from the competition. Additionally, Akebia Therapeutics possesses a robust portfolio of intellectual property rights and patents. This provides the company with legal protection and exclusivity for its innovative products, preventing competitors from easily replicating their successes. Furthermore, Akebia Therapeutics has established strategic partnerships and collaborations with renowned pharmaceutical companies. These partnerships not only provide access to additional resources and expertise but also enhance the company's credibility and reputation within the industry. Lastly, Akebia Therapeutics has a dedicated and talented team of researchers, scientists, and professionals who are committed to advancing the company's mission of improving patient outcomes. This highly skilled workforce enables Akebia to stay at the forefront of medical advancements and deliver high-quality therapeutics to the market.

Weaknesses

Despite its strengths, Akebia Therapeutics Inc also faces certain weaknesses that could hinder its growth and competitive position. Firstly, the company relies heavily on the success of its pipeline products. Any setbacks or failures in the clinical development of these products may significantly impact the company's financial performance and overall reputation. Additionally, Akebia Therapeutics operates in a highly regulated industry, requiring compliance with strict regulatory standards and significant investment in research and development. This can pose financial and resource constraints for the company, limiting its ability to quickly bring new products to market. Furthermore, Akebia Therapeutics may face challenges related to market acceptance and competition. The pharmaceutical industry is highly competitive, with numerous established players competing for market share. Successfully commercializing new products and gaining market acceptance can be challenging and time-consuming. Lastly, Akebia Therapeutics may face risks related to dependence on key partners and collaborators. Any changes in these partnerships, such as termination or loss of intellectual property rights, could negatively impact the company's operations and future growth prospects.

Opportunities

Akebia Therapeutics Inc has several opportunities to leverage and capitalize on in the market. Firstly, the increasing global prevalence of kidney diseases presents a substantial opportunity for the company to address unmet medical needs and capture a larger market share. By developing effective and innovative therapeutics, Akebia can position itself as a key player in the treatment of kidney diseases. Moreover, advancements in technology and understanding of disease mechanisms offer opportunities for Akebia Therapeutics to explore new treatment approaches and expand its therapeutic portfolio. The company can invest in research and development to discover novel drug candidates and strengthen its competitive position. Additionally, Akebia Therapeutics can explore strategic partnerships and collaborations with academic institutions and research organizations. These collaborations can provide access to novel technologies, scientific expertise, and potential funding sources, facilitating the development of new therapies and strengthening the company's research capabilities. Lastly, the growing trend towards personalized medicine and precision therapies allows Akebia Therapeutics to tailor its treatments to individual patients. By leveraging personalized medicine approaches, the company can enhance treatment efficacy and patient outcomes while differentiating itself from competitors.

Threats

Akebia Therapeutics Inc faces several threats that could have a negative impact on its business and market position. Firstly, the pharmaceutical industry is subject to stringent regulations and compliance requirements, which can pose challenges for approval and commercialization of new products. Delays or failures in obtaining regulatory approvals can significantly hinder the company's ability to generate revenue and expand its market presence. Moreover, the competitive landscape within the pharmaceutical industry is intensifying. Akebia Therapeutics faces competition from both established pharmaceutical companies and emerging biotechnology firms. These competitors may develop similar or more effective therapeutics, eroding Akebia's market share and posing challenges for commercial success. Additionally, changes in healthcare policies or reimbursement systems can impact the affordability and accessibility of Akebia's therapeutics. Reductions in healthcare budgets or changes in reimbursement rates may limit patient access to Akebia's products, affecting the company's financial performance. Lastly, evolving market dynamics and economic uncertainties can pose risks for Akebia Therapeutics. Market volatility, fluctuating exchange rates, and economic downturns can impact the company's revenue streams, profitability, and ability to secure funding for research and development.

In conclusion, Akebia Therapeutics Inc has a solid foundation of strengths, but it also faces challenges and uncertainties. By capitalizing on its strengths, proactively addressing weaknesses, exploring opportunities, and mitigating threats, Akebia can position itself for long-term success and growth in the competitive pharmaceutical industry.

Akebia Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Akebia Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Akebia Therapeutics shares outstanding

The number of shares was Akebia Therapeutics in 2023 — This indicates how many shares 187.465 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Akebia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Akebia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Akebia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Akebia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Akebia Therapeutics.

Akebia Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.05 -0.04  (26.47 %)2024 Q2
3/31/2024-0.08 -0.09  (-15.09 %)2024 Q1
12/31/2023-0.04 0  (100 %)2023 Q4
9/30/2023-0.09 -0.08  (7.73 %)2023 Q3
6/30/2023-0.03 -0.06  (-135.29 %)2023 Q2
3/31/2023-0.15 -0.14  (8.5 %)2023 Q1
12/31/2022-0.19 -0.04  (78.99 %)2022 Q4
9/30/2022-0.15 -0.28  (-83.01 %)2022 Q3
6/30/2022-0.32 0.23  (171.76 %)2022 Q2
3/31/2022-0.29 -0.35  (-19.01 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Akebia Therapeutics stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

61

👫 Social

85

🏛️ Governance

40

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept✅
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Akebia Therapeutics shareholders

%
Name
Stocks
Change
Date
7.70608 % Alerce Investment Management, L.P.16,205,119012/31/2023
3.61761 % The Vanguard Group, Inc.7,607,47286,15512/31/2023
3.28856 % Acadian Asset Management LLC6,915,503-307,98512/31/2023
2.27276 % Renaissance Technologies LLC4,779,3831,623,95612/31/2023
1.23638 % Millennium Management LLC2,599,987-452,73812/31/2023
1.19590 % BlackRock Institutional Trust Company, N.A.2,514,85972,98412/31/2023
1.02685 % Susquehanna International Group, LLP2,159,3641,408,92312/31/2023
0.92953 % Jacobs Levy Equity Management, Inc.1,954,718134,92312/31/2023
0.85676 % Geode Capital Management, L.L.C.1,801,69077,41612/31/2023
0.85299 % Butler (John P)1,793,760-130,7922/29/2024
1
2
3
4
5
...
10

Akebia Therapeutics Executives and Management Board

Mr. John Butler59
Akebia Therapeutics President, Chief Executive Officer, Director (since 2013)
Compensation 3.04 M
Dr. Steven Burke62
Akebia Therapeutics Senior Vice President - Research and Development, Chief Medical Officer
Compensation 1.38 M
Mr. Michel Dahan44
Akebia Therapeutics Chief Operating Officer, Senior Vice President
Compensation 1.29 M
Ms. Nicole Hadas50
Akebia Therapeutics Senior Vice President, Chief Legal Officer, Corporate Secretary
Compensation 1.24 M
Mr. Adrian Adams72
Akebia Therapeutics Independent Chairman of the Board
Compensation 110,209
1
2
3

Most common questions regarding Akebia Therapeutics

What values and corporate philosophy does Akebia Therapeutics represent?

Akebia Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. The company strives to develop novel therapies to address unmet medical needs and improve patient outcomes. Akebia embraces a corporate philosophy centered around scientific excellence, integrity, and a commitment to advancing healthcare. By conducting rigorous research and fostering partnerships, Akebia aims to revolutionize the treatment landscape for patients worldwide. With a focus on bringing transformative therapies to market, Akebia Therapeutics Inc is dedicated to enhancing the lives of patients and making a lasting impact on the healthcare industry.

In which countries and regions is Akebia Therapeutics primarily present?

Akebia Therapeutics Inc primarily operates in the United States and has a significant presence in various regions within the country. As a biopharmaceutical company, Akebia Therapeutics focuses on discovering, developing, and commercializing innovative therapies to address unmet medical needs. With its headquarters located in Cambridge, Massachusetts, Akebia Therapeutics caters to patients across the United States, offering its specialized treatments for conditions such as anemia caused by chronic kidney disease. This American-based company's commitment to improving patient outcomes and advancing medical research has solidified its position in the healthcare industry.

What significant milestones has the company Akebia Therapeutics achieved?

Akebia Therapeutics Inc has achieved several significant milestones. The company successfully received marketing approval for its drug, Auryxia, which is indicated for the treatment of iron deficiency anemia in patients with chronic kidney disease. Akebia has also entered into collaborations with top pharmaceutical companies to further develop and commercialize its products. Additionally, the company has conducted successful clinical trials for its investigational drug, Vadadustat, as a potential treatment for anemia associated with chronic kidney disease. Akebia Therapeutics Inc has shown consistent growth and innovation in the pharmaceutical industry, positioning itself as a leading player in the development of therapies for renal and metabolic disorders.

What is the history and background of the company Akebia Therapeutics?

Akebia Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with kidney disease. Founded in 2007, the company has a strong history in researching and developing novel drugs targeted at treating anemia and other complications of chronic kidney disease. Akebia Therapeutics Inc has built a robust pipeline of potential therapies, with its lead product candidate being vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The company strives to improve patient outcomes and enhance their quality of life through its dedication to advancing kidney disease treatments. Akebia Therapeutics Inc has become a recognized name in the pharmaceutical industry due to its commitment to innovation and research in the field of kidney disease.

Who are the main competitors of Akebia Therapeutics in the market?

The main competitors of Akebia Therapeutics Inc in the market include pharmaceutical companies such as FibroGen Inc, GlaxoSmithKline plc, and Keryx Biopharmaceuticals Inc.

In which industries is Akebia Therapeutics primarily active?

Akebia Therapeutics Inc is primarily active in the biopharmaceutical industry. Their focus lies in the research, development, and commercialization of innovative therapies to address unmet medical needs. With a dedication to addressing kidney diseases and other serious conditions, Akebia Therapeutics Inc aims to improve patient outcomes and quality of life. Through their strategic partnerships and robust pipeline, the company aims to advance their therapeutic solutions and make a positive impact in the healthcare sector.

What is the business model of Akebia Therapeutics?

The business model of Akebia Therapeutics Inc is focused on the development and commercialization of innovative therapeutics for patients with kidney diseases. Akebia employs a research-driven approach to develop therapies that address unmet medical needs in the kidney disease market. The company's flagship product, Auryxia, is an oral medication approved for the treatment of anemia due to chronic kidney disease in adult patients. Akebia is also engaged in developing potential treatments for other kidney-related conditions, such as diabetic kidney disease. By leveraging its scientific expertise and strategic partnerships, Akebia aims to improve patient outcomes and contribute to the advancement of kidney disease management.

What is the P/E ratio of Akebia Therapeutics 2024?

The Akebia Therapeutics P/E ratio is -5.85.

What is the P/S ratio of Akebia Therapeutics 2024?

The Akebia Therapeutics P/S ratio is 1.74.

What is the Quality Investing of Akebia Therapeutics?

The Quality Investing for Akebia Therapeutics is 4/10.

What is the revenue of Akebia Therapeutics 2024?

The expected Akebia Therapeutics revenue is 175.44 M USD.

How high is the profit of Akebia Therapeutics 2024?

The expected Akebia Therapeutics profit is -52.19 M USD.

What is the business model of Akebia Therapeutics

Akebia Therapeutics Inc is a biopharmaceutical company focusing on the development and commercialization of innovative therapies for the treatment of kidney diseases. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Akebia's business model is based on the development and commercialization of products for the treatment of anemia, a common complication in chronic kidney diseases. The company specializes in developing therapies that can increase hemoglobin levels in the blood and slow the progression of kidney disease. Akebia has already developed several products that are in different stages of clinical development. One of Akebia's leading products is Vadadustat, an oral medication for the treatment of anemia in chronic kidney disease. Vadadustat is currently in Phase III trials to evaluate its effectiveness and safety in patients with advanced-stage chronic kidney disease. Akebia has also entered into an agreement with Otsuka Pharmaceutical Co. Ltd., a leading Japanese pharmaceutical company. The agreement stipulates that Otsuka will market Vadadustat in Japan and most other Asian countries. Akebia will be responsible for the development, manufacturing, and marketing of Vadadustat in the US and Europe. Furthermore, Akebia has other promising products in the pipeline, including AKB-5169, another oral medication for the treatment of anemia in patients with chronic kidney disease. AKB-5169 is currently in Phase II trials. The company has also established a strong partnership with Mitsubishi Tanabe Pharma Corporation. This partnership focuses on the development and commercialization of therapies for the treatment of kidney diseases. Akebia will handle the development and manufacturing of therapies, while Mitsubishi Tanabe Pharma Corporation will be responsible for the marketing and distribution in Japan. Akebia has also focused on building a strong research and development department. The company has developed a platform technology called HIF (Hypoxia Inducible Factor), which enables the discovery and development of new therapies for the treatment of kidney diseases. This technology utilizes the body's natural mechanism to increase oxygen transport in the blood. Overall, Akebia has built a promising business model based on the development and commercialization of innovative therapies for the treatment of kidney diseases. The company has already developed several promising products in the pipeline and established strong partnerships with leading pharmaceutical companies. Akebia also has a strong research and development department, allowing the company to continue discovering and developing new therapies for the treatment of kidney diseases.

What is the Akebia Therapeutics dividend?

Akebia Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Akebia Therapeutics pay dividends?

The dividend cannot currently be calculated for Akebia Therapeutics or the company does not pay out a dividend.

What is the Akebia Therapeutics ISIN?

The ISIN of Akebia Therapeutics is US00972D1054.

What is the Akebia Therapeutics WKN?

The WKN of Akebia Therapeutics is A1XF0S.

What is the Akebia Therapeutics ticker?

The ticker of Akebia Therapeutics is AKBA.

How much dividend does Akebia Therapeutics pay?

Over the past 12 months, Akebia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Akebia Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Akebia Therapeutics?

The current dividend yield of Akebia Therapeutics is .

When does Akebia Therapeutics pay dividends?

Akebia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Akebia Therapeutics?

Akebia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Akebia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Akebia Therapeutics located?

Akebia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Akebia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Akebia Therapeutics from 10/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/30/2024.

When did Akebia Therapeutics pay the last dividend?

The last dividend was paid out on 10/30/2024.

What was the dividend of Akebia Therapeutics in the year 2023?

In the year 2023, Akebia Therapeutics distributed 0 USD as dividends.

In which currency does Akebia Therapeutics pay out the dividend?

The dividends of Akebia Therapeutics are distributed in USD.

All fundamentals about Akebia Therapeutics

Our stock analysis for Akebia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Akebia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.